{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:32:08Z","timestamp":1789824728437,"version":"4.0.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00381-025-06822-4","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T22:49:26Z","timestamp":1745880566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel surgical approach for intraventricular cerliponase alfa enzyme replacement therapy via central venous access device (CVAD) port in neuronal ceroid lipofuscinosis type 2 (CLN2) disease"],"prefix":"10.1007","volume":"41","author":[{"given":"Scott","family":"Boop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Nistal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriel","family":"Barrios-Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Bruce","family":"Cherny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene J.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Shelkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Kho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah E.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hauptman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"6822_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pediatrneurol.2020.04.018","volume":"110","author":"RE de Los","year":"2020","unstructured":"de Los RE, Lehwald L, Augustine EF et al (2020) Intracerebroventricular cerliponase alfa for neuronal ceroid lipofuscinosis type 2 disease: clinical practice considerations from US clinics. Pediatr Neurol 110:64\u201370. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2020.04.018","journal-title":"Pediatr Neurol"},{"issue":"1","key":"6822_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13023-021-01813-5","volume":"16","author":"SE Mole","year":"2021","unstructured":"Mole SE, Schulz A, Badoe E et al (2021) Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet J Rare Dis 16(1):185. https:\/\/doi.org\/10.1186\/s13023-021-01813-5","journal-title":"Orphanet J Rare Dis"},{"key":"6822_CR3","doi-asserted-by":"publisher","unstructured":"Leppert HG, Anderson JT, Timm KJ, et al (2023) Sortilin inhibition treats multiple neurodegenerative lysosomal storage disorders. bioRxiv.https:\/\/doi.org\/10.1101\/2023.09.22.559064","DOI":"10.1101\/2023.09.22.559064"},{"issue":"20","key":"6822_CR4","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","volume":"378","author":"A Schulz","year":"2018","unstructured":"Schulz A, Ajayi T, Specchio N et al (2018) Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med 378(20):1898\u20131907. https:\/\/doi.org\/10.1056\/NEJMoa1712649","journal-title":"N Engl J Med"},{"issue":"1","key":"6822_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/s1474-4422(23)00384-8","volume":"23","author":"A Schulz","year":"2024","unstructured":"Schulz A, Specchio N, de Los RE et al (2024) Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study. Lancet Neurol 23(1):60\u201370. https:\/\/doi.org\/10.1016\/s1474-4422(23)00384-8","journal-title":"Lancet Neurol"},{"key":"6822_CR6","unstructured":"Seattle Children\u2019s Hospital. (2023). Brineura (cerliponase alfa): intraventricular infusion for CLN2 disease. http:\/\/seattlechildrens.policystat.com\/policy\/8546623\/"},{"issue":"5","key":"6822_CR7","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1111\/cts.13028","volume":"14","author":"K Hammon","year":"2021","unstructured":"Hammon K, de Hart G, Vuillemenot BR et al (2021) Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease. Clin Transl Sci 14(5):1810\u20131821. https:\/\/doi.org\/10.1111\/cts.13028","journal-title":"Clin Transl Sci"},{"key":"6822_CR8","unstructured":"BioMarin Pharmaceuticals Inc. (2020). Brineura (ceroliponase alfa) dosing and administration guide. https:\/\/hcp.biomarin.com\/en-us\/brineura\/wp-content\/uploads\/sites\/2\/2022\/10\/Brineura-Dosing-and-Administration-Guide.pdf?v=0.5"},{"issue":"11","key":"6822_CR9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/21678707.2020.1856654","volume":"8","author":"SC Aylward","year":"2020","unstructured":"Aylward SC, Pindrik J, Abreu NJ, Cherny WB, O\u2019Neal M, de Los RE (2020) Cerliponase alfa for CLN2 disease, a promising therapy. Expert Opinion on Orphan Drugs 8(11):445\u2013454. https:\/\/doi.org\/10.1080\/21678707.2020.1856654","journal-title":"Expert Opinion on Orphan Drugs"},{"issue":"1","key":"6822_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3171\/2021.7.Peds21129","volume":"29","author":"CL Craven","year":"2022","unstructured":"Craven CL, Gissen P, Bower R, Lee L, Aquilina K, Thompson DNP (2022) A survival analysis of ventricular access devices for delivery of cerliponase alfa. J Neurosurg Pediatr 29(1):115\u2013121. https:\/\/doi.org\/10.3171\/2021.7.Peds21129","journal-title":"J Neurosurg Pediatr"},{"key":"6822_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejpn.2020.12.002","volume":"30","author":"B Estublier","year":"2021","unstructured":"Estublier B, Cano A, Hoebeke C et al (2021) Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: the first French cohort. Eur J Paediatr Neurol 30:17\u201321. https:\/\/doi.org\/10.1016\/j.ejpn.2020.12.002","journal-title":"Eur J Paediatr Neurol"},{"key":"6822_CR12","doi-asserted-by":"publisher","first-page":"556802","DOI":"10.3389\/fped.2020.556802","volume":"8","author":"D Li","year":"2020","unstructured":"Li D, Stellpflug W, Romanski K, Kilgallon M, Speck S, Saratsis AM (2020) Ventricular cerebrospinal fluid sampling in pediatric diffuse midline glioma patients: institutional experience and review of the literature. Front Pediatr 8:556802. https:\/\/doi.org\/10.3389\/fped.2020.556802","journal-title":"Front Pediatr"},{"issue":"4","key":"6822_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3171\/2019.11.PEDS19320","volume":"25","author":"A Palpan Flores","year":"2020","unstructured":"Palpan Flores A, Saceda Guti\u00e9rrez J, Brin Reyes JR, Sierra Tamayo J, Carceller BF (2020) Risk factors associated with conversion of an Ommaya reservoir to a permanent cerebrospinal fluid shunt in preterm posthemorrhagic hydrocephalus. J Neurosurg Pediatr 25(4):417\u2013424. https:\/\/doi.org\/10.3171\/2019.11.PEDS19320","journal-title":"J Neurosurg Pediatr"},{"issue":"3","key":"6822_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jinf.2013.12.002","volume":"68","author":"AD Szvalb","year":"2014","unstructured":"Szvalb AD, Raad II, Weinberg JS, Suki D, Mayer R, Viola GM (2014) Ommaya reservoir-related infections: clinical manifestations and treatment outcomes. J Infect 68(3):216\u2013224. https:\/\/doi.org\/10.1016\/j.jinf.2013.12.002","journal-title":"J Infect"},{"issue":"10298","key":"6822_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0140-6736(21)00766-2","volume":"398","author":"JG Moss","year":"2021","unstructured":"Moss JG, Wu O, Bodenham AR, Agarwal R, Menne TF, Jones BL, Heggie R, Hill S, Dixon-Hughes J, Soulis E, Germeni E, Dillon S, McCartney E, CAVA trial group (2021) Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial. Lancet 398(10298):403\u2013415. https:\/\/doi.org\/10.1016\/S0140-6736(21)00766-2","journal-title":"Lancet"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-025-06822-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00381-025-06822-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-025-06822-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:16:25Z","timestamp":1770815785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00381-025-06822-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["6822"],"URL":"https:\/\/doi.org\/10.1007\/s00381-025-06822-4","relation":{},"ISSN":["0256-7040","1433-0350"],"issn-type":[{"value":"0256-7040","type":"print"},{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"172"}}